Automatic Eye Disease Screening System

眼病自动筛查系统

• 批准号: 7924996
• 负责人: Robert B Avery
• 金额: $ 288.49万
• 依托单位: VISIONQUEST BIOMEDICAL, LLC
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7924996
• 关键词: Address; Age related macular degeneration; Algorithms; American; Applications Grants; Area; Asia; Asians; Attention; Automation; Blindness; Caring; Centers for Disease Control and Prevention (U.S.); Clinic; Clinical Protocols; Clinical Research; Communication; Community Healthcare; Computer Assisted; Computer software; Computer-Assisted Diagnosis; Computers; Country; Data; Data Collection; Data Set; Development; Diabetes Mellitus; Diabetic Retinopathy; Diagnosis; Documentation; Early Diagnosis; Economics; Elements; Europe; European; Eye; Eye diseases; FDA approved; Foundations; Glaucoma; Goals; Grant; Guidelines; Health Insurance Portability and Accountability Act; Health Personnel; Health Sciences; Health Services Accessibility; Healthcare; Healthcare Systems; Human; Hybrids; Image; Image Analysis; Individual; Information Systems; Institutes; International; Internet; Intervention; Joint Ventures; Lead; Mammography; Manuals; Marketing; Measures; Medical; Methods; Multi-Institutional Clinical Trial; New Mexico; Occupations; Ophthalmic examination and evaluation; Ophthalmologist; Optics; Optometrist; Pap smear; Performance; Populations at Risk; Productivity; Quality of life; Reader; Reading; Recruitment Activity; Reporting; Research; Research Infrastructure; Retina; Retinal; Retinal Diseases; Risk; Screening procedure; Security; Sensitivity and Specificity; Services; Site; Software Engineering; Solutions; South Texas; Specialist; Staging; System; Technology; Testing; Texas; Time; Training; Universities; Validation; Vision; base; clinical research site; cost; diabetic; diabetic patient; improved; meetings; programs; prospective; prototype; public health relevance; research and development; software development; software systems; success

DESCRIPTION (provided by applicant): This proposed project is motivated by the fact that comprehensive, broad-scale screening for eye diseases such as age-related macular degeneration (AMD) and diabetic retinopathy (DR) is economically prohibitive without the introduction of computer-assisted diagnosis of retinal images. According to the CDC approximately 80 million people in the U.S. have some form of eye disease, including 20 million diabetics at risk for retinopathy, 60 million at risk for glaucoma, and 13 million diagnosed with AMD. It is estimated that less than half of those individuals with diabetes are screened periodically for DR. Lack of medical coverage and access to healthcare providers imposes major obstacles for nearly 10 million diabetics. Creating an affordable and accessible solution to providing screening services to these diabetics presents a significant challenge to the healthcare community. A comprehensive screening program for U.S. citizens utilizing ophthalmologists, optometrists, or other trained specialists, "readers", to grade each case would be prohibitively expensive. The solution is to implement a computer-assisted technology similar to other medical applications, such as mammograms and Pap smears; that would provide comprehensive, periodic screening of our at-risk population. This grant will implement an automatic eye disease screening system (AEDSS) which will enable highly efficient screening at centers across the US and globally. This grant will conduct a comprehensive multi-site clinical study to implement a inter-connected regional system to evaluate the efficiency of computer-based algorithms. The study will be made possible through the implementation of the infrastructure for a reading center in South Texas where it is estimated that nearly 200,000 diabetics reside and over 50% do not receive annual examinations. The center will be a demonstration site where the efficacy of the software can be documented for submission to the FDA for pre-market approval (PMA). The goal is to show that a center's throughput, i.e. number of cases screened per time period, will increase five fold through the use of a hybrid (automation-human graders) approach with sensitivity that is comparable or better than solely human-based screening. The significance of this proposed research is two-fold. First, by increasing the productivity of reading centers through automation, a much larger population of at-risk diabetics will have access to this service, leading to improved productivity and quality of life through early detection and treatment. Second, by providing a FDA approved system for highly effective DR screening, the US healthcare system would benefit economically through the added efficiency of our system. Our system does not replace current human readers; it simply allows an increase of throughput of cases by factors of five or more without sacrificing sensitivity and specificity. The reduced cost of screening would lead to more reading centers and increased high-paying technical/medical jobs.

描述（由申请人提供）：该提出的项目是由以下事实激发的：与年龄相关的黄斑变性（AMD）和糖尿病性视网膜病变（DR）的全面，广泛的筛查，而没有引入计算机辅助诊断的视网膜图像。根据美国疾病预防控制中心（CDC）的说法，美国约有8000万人患有某种形式的眼科疾病，其中包括有2000万个糖尿病患者患视网膜病的风险，有6000万人患有青光眼的风险和1300万诊断为AMD的糖尿病患者。据估计，对于DR的糖尿病患者中，只有不到一半的糖尿病患者进行筛查。缺乏医疗保险和获得医疗保健提供者的机会，对近1000万个糖尿病患者施加了主要障碍。为这些糖尿病患者提供筛查服务的负担得起且易于使用的解决方案给医疗保健社区带来了重大挑战。利用眼科医生，验光师或其他训练有素的专家“读者”，为美国公民提供的全面筛查计划将非常昂贵。解决方案是实施类似于其他医学应用的计算机辅助技术，例如乳房X线照片和子宫颈抹片检查；这将为我们的高危人口提供全面的周期性筛查。该赠款将实施自动眼病筛查系统（AEDSS），该系统将在美国和全球的中心进行高效的筛查。该赠款将进行一项全面的多站点临床研究，以实施一个相互连接的区域系统来评估基于计算机的算法的效率。这项研究将通过在南德克萨斯州的阅读中心实施基础设施来实现，据估计，据估计，将近20万糖尿病患者居住，超过50％的人未接受年度考试。该中心将是一个示范站点，可以将软件的功效记录在FDA中以进行前市场批准（PMA）。目的是证明中心的吞吐量，即每个时间段筛选的案例数，通过使用混合（自动化 - 人类级别的毕业生）方法的灵敏度可比性或更好的人类基于人类的筛选，将增加五倍。这项拟议的研究的意义是两倍。首先，通过通过自动化提高阅读中心的生产率，高危糖尿病患者人群将可以使用这项服务，从而通过早期发现和治疗提高了生产率和生活质量。其次，通过提供FDA批准的高效DR筛查系统，美国医疗保健系统将通过我们系统的额外效率在经济上受益。我们的系统不能取代当前的人类读者；它只是允许通过五个或更多的因素增加案例的吞吐量，而不会牺牲灵敏度和特异性。筛查成本降低将导致更多的阅读中心，并增加高薪技术/医疗工作。